The purpose of this resea4rch study is to evaluate the durability of the effectiveness and safety of a study drug called droxidopa (also known by the trade name NORTHERATM) in people with symptomatic Neurogenic Orthostatic Hypotension (NCH)
Who may be Eligible
This is a double-blind placebo controlled, intervention study that can last up to 36 weeks. Eligible patients must be at least 18 years of age and have any of the diagnoses listed. Once enrolled, patient will be randomized "like flipping a coin" into 2 groups. Group 1 will receive droxidopa and Group 2 will receive placebo. This part of the study is double-blind which means that neither the study staff or study patients will know which group participants are in.